MARKHAM, ON / ACCESS Newswire / August 19, 2025 / iFabric Corp. (TSX:IFA)(OTCQX:IFABF), is pleased to announce that the results of its clinical trial, "Antimicrobial-treated fabric scrubs can prevent pathogen proliferation on scrubs", has been officially published in the Journal of Hospital Infection, the editorially independent scientific publication of the Healthcare Infection Society. The aim of the Journal is to publish high quality research and information relating to infection prevention and control that is relevant to an international audience.

~Full Commercial Launch with Expanded Number of Instrument Sets and Field Support to Meet Growing Market Demand ~ ~ New SI Joint Fixation Device Offers a Reduced Profile in Implant Size Providing Physicians Choices for Varying Anatomy and Treatment Strategies with the Catamaran Technology ~ LOS GATOS, CA / ACCESS Newswire / August 19, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain sacro-pelvic disorders, today announced the full commercial market launch of its new Catamaran® SE SI Joint Fusion System. The Catamaran SE Fixation Device expands the Company's implant portfolio, providing physicians with a smaller implant option for sacroiliac (SI) joint fusion procedures.

Revolutionary Plant-Based Technology Gains Momentum as a Game-Changer in Wound Management ANN ARBOR, MI / ACCESS Newswire / August 12, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering advanced diagnostic and therapeutic solutions for equine and companion animals, is pleased to announce the next installment of its Fourth Friday at Four webinar series, scheduled for Friday, August 22, 2025, at 4:00 PM ET. This month's session will highlight VETIGEL® hemostatic gel, Zomedica's innovative, plant-based solution designed for rapid and effective control of bleeding.

Ryder's pivot to contractual, asset-light revenue streams and growth in SCS/DTS segments enhances resilience and positions the company for long-term expansion. Strong Q2 results, robust free cash flow, and attractive valuation make Ryder appealing for value-oriented investors seeking double-digit earnings growth through FY27. Strategic initiatives, including AI-driven logistics, Cardinal Logistics integration, and fleet optimization, are driving margin expansion and operational efficiency.

I am reiterating my buy rating as I see more upside to come. Despite stagnant revenue growth, bottom-line performance still tracks well. EPS continues to grow with double digits as the management improves contractual earnings and improves operational efficiency. Free cash flow forecasts have been improved by more than $500 million, as the company expects reinstated tax bonus depreciation. The stock still trades at a discount with 60% upside potential.

Vancouver, British Columbia--(Newsfile Corp. - August 7, 2025) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or the "Company"), a consumer packaged goods company in the health and wellness sector, is pleased to announce the upcoming launch of its new convenient 6-Count Sleep Gummies in key Middle Eastern markets in collaboration with its distribution partner in Saudi Arabia. This expansion will focus on the Gulf Cooperation Council (GCC) region, a high-growth market for wellness and sleep-support products.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Clinical data and cost-effectiveness analysis demonstrates the VenoValve would provide both better health outcomes and lower costs compared to current standard of care treatments The VenoValve could potentially save $5.9 billion annually in healthcare costs for the approximately 2.5 million U.S. patients with severe CVI Company to host live webcast with lead author of the cost-analysis manuscript, today, August 6th, at 12:00 PM ET; Access the Webcast Here IRVINE, CA / ACCESS Newswire / August 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announcedpreliminary findings from a VenoValve health economic study, which indicate that the VenoValve would be a cost-effective treatment option for patients with severe Chronic Venous Insufficiency (CVI) caused by deep valvular incompetency. The Company announced it will host a live webcast to discuss the cost-effectiveness analysis results today, Wednesday, August 6th at 12:00 PM ET (details below).

~ SiVantage Portfolio Acquisition Enhances Tenon's Sacroiliac Joint Fusion Capabilities with a Unique Multi-Product, Multi-Approach Solution ~ ~ Significant Enhancement of Tenon Medical's Commercial Leadership to Accelerate Growth Initiatives ~ ~ Reinforces Tenon's Commitment to Fusion-Driven Innovation and Data-Backed Outcomes in a Rapidly Evolving Market ~ LOS GATOS, CA / ACCESS Newswire / August 1, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical technology company dedicated to transforming care for patients with sacroiliac joint (SIJ) disorders, today announced it has acquired sacroiliac (SI) joint specific assets from SiVantage, a privately held startup company based in Tampa, Florida. This strategic asset acquisition includes SiVantage's SImmetry® and SImmetry+™ technologies expanding Tenon's SI portfolio across multiple approaches to the variable sacro pelvic anatomy.

VANCOUVER, BC / ACCESS Newswire / August 1, 2025 / Apex Critical Metals Corp. ("Apex" or the "Company") (CSE:APXC)(OTCQX:APXCF)(FWB:KL9) is pleased to announce that OTC Markets Group Inc., operator of regulated markets for trading 12,000 U.S. and international securities, today announced that Apex has qualified to trade on the OTCQX® Best Market. Apex previously traded on the OTCQB® Venture Market.